Pharmamel Drug Discovery

Pharmamel is a Spanish biotechnology company specializing in the development of melatonin-based therapies for severe inflammatory conditions and skin protection. Founded as a spin-off from the University of Granada, the company leverages decades of research into the antioxidant and anti-inflammatory properties of melatonin. Its lead clinical program is an intravenous melatonin formulation for the treatment of sepsis, which has shown promising results in reducing mortality and systemic inflammation. Additionally, Pharmamel develops topical treatments to prevent radiodermatitis in cancer patients and high-end dermo-cosmetic products for skin regeneration.